Literature DB >> 30805992

Initial experience with laparoscopic and robotic surgery for the treatment of periampullary tumours: single institution experience with the first 30 consecutive cases.

Brian K P Goh1,2, Tze-Yi Low1, Juinn-Huar Kam1, Ser-Yee Lee1,2, Chung-Yip Chan1,2.   

Abstract

BACKGROUND: Concerns have been raised about the safety of minimally invasive surgery (MIS) for pancreatoduodenectomy (PD) during the early learning phase. In this study, we present our initial experience with MIS for periampullary tumours.
METHODS: Retrospective review of the first 30 consecutive patients who underwent laparoscopic (LS)/robotic surgery (RS) for periampullary tumours between 2014 and 2017.
RESULTS: Twenty-seven patients underwent PD, including three total pancreatectomies (TPs) and three underwent palliative bypasses. Twenty underwent LS, of which 18 were hybrid PDs, including two TPs and two bypasses. Ten patients underwent RS, of which nine were PDs, including one TP and one bypass. Five of 10 RSs were totally MIS procedures. There were four PDs with venous resection, of which three were by RS. There were four (13.3%) open conversions all in the LS cohort. There were five (16.7%) major (>grade 2) morbidities, including three pancreatic fistulas (two grade B and one grade C). There was no 30-day and one (3.3%) 90-day mortality. Comparison between RS and LS demonstrated that RS had a higher likelihood of being completed via totally MIS (five (50%) versus 0, P = 0.002), tended to have a shorter post-operative stay (eight (range 6-36) versus 14.5 (range 6-62) days, P = 0.058) but tended to be associated with a longer operation time (670 (range 500-930) versus 577 (range 235-715) min, P = 0.056).
CONCLUSION: Our initial experience demonstrated that both LS and RS can be safely adopted for the treatment of periampullary tumours. The learning curve for RS seemed to be shorter than LS as we could transition more quickly from hybrid PDs to totally MIS safely.
© 2019 Royal Australasian College of Surgeons.

Entities:  

Keywords:  laparoscopic pancreatectomy; laparoscopic pancreatoduodenectomy; robotic pancreatectomy; robotic pancreatoduodenectomy; whipples procedure

Mesh:

Year:  2019        PMID: 30805992     DOI: 10.1111/ans.15033

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  4 in total

Review 1.  International expert consensus on laparoscopic pancreaticoduodenectomy.

Authors:  Renyi Qin; Michael L Kendrick; Christopher L Wolfgang; Barish H Edil; Chinnusamy Palanivelu; Rowan W Parks; Yinmo Yang; Jin He; Taiping Zhang; Yiping Mou; Xianjun Yu; Bing Peng; Palanisamy Senthilnathan; Ho-Seong Han; Jae Hoon Lee; Michiaki Unno; Steven W M Olde Damink; Virinder Kumar Bansal; Pierce Chow; Tan To Cheung; Nim Choi; Yu-Wen Tien; Chengfeng Wang; Manson Fok; Xiujun Cai; Shengquan Zou; Shuyou Peng; Yupei Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

2.  Changing trends and outcomes associated with the adoption of minimally-invasive pancreato-biliary surgery: Contemporary experience of a 'self-taught' early adopter in Southeast Asia.

Authors:  Brian K P Goh; Gerald Zeng; Tze-Yi Low; Darren W Chua; Ye-Xin Koh; Kai-Inn Lim
Journal:  J Minim Access Surg       Date:  2020 Oct-Dec       Impact factor: 1.407

3.  Changing trends and outcomes associated with the adoption of minimally invasive pancreatic surgeries: A single institution experience with 150 consecutive procedures in Southeast Asia.

Authors:  Brian K Goh; Tze Yi Low; Ye Xin Koh; Ser Yee Lee; Jin-Yao Teo; Juinn Huar Kam; Prema Raj Jeyaraj; Peng-Chung Cheow; Pierce K Chow; London L Ooi; Alexander Y Chung; Chung Yip Chan
Journal:  J Minim Access Surg       Date:  2020 Oct-Dec       Impact factor: 1.407

4.  Robotic Versus Laparoscopic Pancreaticoduodenectomy: An Up-To-Date System Review and Meta-Analysis.

Authors:  Lanwei Ouyang; Jia Zhang; Qingbo Feng; Zhiguang Zhang; Hexing Ma; Guodong Zhang
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.